Medicare Drug Price Negotiations Yield $12 Billion Savings on 15 Key Medications
The Trump administration has announced reduced Medicare prices for 15 widely used prescription drugs under the Medicare drug price negotiation program established by the Inflation Reduction Act. The focus was on high-expenditure drugs for conditions such as cancer, diabetes, and respiratory treatments. These negotiated prices are the amounts paid by Medicare, not out-of-pocket patient costs, and are projected to save Medicare approximately $12 billion compared to last year.